January 26, 2015 9:04 PM ET

Biotechnology

Company Overview of Galena Biopharma, Inc.

Company Overview

Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology treatments that address major unmet medical needs to advance cancer care. Its commercial product includes Abstral, a sublingual tablet, which is used as treatment option for breakthrough cancer pain in patients. The company’s lead product candidate comprise NeuVax (nelipepimut-S or E75), which has completed Phase III clinical trials for preventing the recurrence of breast cancer; and Phase IIb clinical trials in combination with Herceptin for the treatment of breast cancer. It also develops GALE-301 or Folate Binding Protein (FBP), a therapeutic target that has completed Phase II clinical ...

4640 SW Macadam Avenue

Suite 270

Portland, OR 97239

United States

Founded in 2003

60 Employees

Phone:

855-855-4253

Key Executives for Galena Biopharma, Inc.

Chief Executive Officer
Age: 59
Total Annual Compensation: $490.0K
Chief Financial Officer
Age: 44
Total Annual Compensation: $236.0K
Compensation as of Fiscal Year 2013.

Galena Biopharma, Inc. Key Developments

Galena Biopharma Hires Joseph Lasaga as Vice President, Business Development and Alliance Management

Galena Biopharma, Inc. announced it has hired Joseph Lasaga as Vice President, Business Development and Alliance Management, reporting to the President and CEO. Mr. Joseph Lasaga has more than 17 years of experience in the biotechnology and pharmaceutical industry in the areas of research and development, business development, alliance management and product strategy. Prior to joining Galena, Mr. Lasaga spent four years at Nektar Therapeutics, most recently as Senior Director, Business Development.

Galena Biopharma Provides Revenue Guidance for the Year 2014 and for the Year 2015

Galena Biopharma provided revenue guidance for the year 2014 and for the year 2015. For the year 2014, revenue in line with expectations and an outlook for 2015 that falls short of the consensus in an update of milestones expected for this year. The biopharmaceutical company expects 2014 revenue in the middle of its range of $8 million to $10 million after having its best quarter to date for sales in fourth quarter. For 2015, the company expects revenue of $15 million to $18 million and expects its Abstral sublingual tablets for cancer pain to become accretive this year.

Galena Biopharma, Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 02:00 PM

Galena Biopharma, Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 02:00 PM. Venue: Club Med, Sandpiper Bay, Florida, United States. Speakers: Mark W. Schwartz, Chief Executive Officer and President.

Similar Private Companies By Industry

Company Name Region
Magellan BioScience Group, Inc. United States
BioAgra, LLC United States
Early Warning Technologies, Inc. United States
MZT Holdings, Inc. United States
Celliance Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Galena Biopharma, Inc., please visit www.galenabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.